Mr Garrambone has executed more than 50 pharmaceutical transactions during his 24-year tenure at Pfizer, where he was a senior vice president of corporate strategic planning.
In addition, Aegerion has announced the transition of Jerry Wisler, co- founder, CEO and director of Aegerion, who has left the company to pursue personal interests.
David Scheer, chairman and co-founder of Aegerion, said: “We are fortunate that Peter is joining the board of directors. His extensive strategic and licensing transaction expertise will be invaluable as the company continues the pursuit of its strategic plan with the availability of its important clinical data in November 2008.”